Volume 29, Number 2—February 2023
Dispatch
Longitudinal Analysis of Electronic Health Information to Identify Possible COVID-19 Sequelae
Table
Diagnostic codes reported during post–COVID-19 interval with increased rate >60 d after acute illness relative to pre–COVID-19 baseline rate, by interval from index date, from large administrative all-payer database, United States, January 2019–December 2020*
Diseases and codes | Rate increase relative to pre–COVID-19 rate (SE)† |
Post–COVID-19 rate, encounters/1,000 person-months |
|||||
---|---|---|---|---|---|---|---|
60–89 d | 90–119 d | 120–149 d | 60–89 d | 90–119 d | 120–149 d | ||
Certain infectious and parasitic diseases | |||||||
B97.21: SARS-associated coronavirus as the cause of diseases classified elsewhere | 28.7 (12.8) | 31.9 (15.6) | 82.2 (39.5) | 0.22 | 0.24 | 0.63 | |
B94.8: Sequelae of other specified infectious and parasitic diseases | 15.4 (4.5) | 17 (5.1) | 11.6 (4.2) | 0.26 | 0.29 | 0.20 | |
A41.53: Sepsis due to Serratia | 6 (3.9) | NS | NS | 0.60 | NS | NS | |
A41.89: Other specified sepsis | 2.8 (0.5) | NS | NS | 0.69 | NS | NS | |
B34.2: Coronavirus infection, unspecified | 2 (0.6) | 2.4 (0.7) | NS | 0.24 | 0.29 | NS | |
R65.21: Severe sepsis with septic shock |
1.5 (0.2) |
NS |
NS |
1.29 |
NS |
NS |
|
Diseases of blood and blood-forming organs and certain disorders involving the immune mechanism | |||||||
D84.821: Immunodeficiency due to drugs |
7.9 (6.0) |
NS |
NS |
0.30 |
NS |
NS |
|
Diseases of the circulatory system | |||||||
B33.24: Viral cardiomyopathy | 9.8 (8.8) | NS | NS | 0.30 | NS | NS | |
I46.8: Cardiac arrest due to other underlying condition | 4.8 (2.3) | 3.5 (1.9) | NS | 0.70 | 0.50 | NS | |
I46.9: Cardiac arrest, cause unspecified | 4.6 (0.9) | 3.7 (0.9) | 4.5 (1.1) | 0.40 | 0.32 | 0.38 | |
I40.0: Infective myocarditis |
NS |
12.6 (10.6) |
NS |
NS |
0.40 |
NS |
|
Diseases of the digestive system | |||||||
K20.91: Esophagitis, unspecified with bleeding | 19.8 (18.4) | NS | NS | 0.30 | NS | NS | |
K21.00: Gastro-esophageal reflux disease with esophagitis, without bleeding | 5.7 (1.3) | 6.1 (1.5) | 5.7 (1.7) | 0.29 | 0.31 | 0.29 | |
K20.90: Esophagitis, unspecified without bleeding | 3.1 (1.4) | 5.8 (2.3) | NS | 0.70 | 0.13 | NS | |
K00.7: Teething syndrome |
NS |
4 (2.3) |
NS |
NS |
0.50 |
NS |
|
Diseases of the genitourinary system | |||||||
N18.31: Chronic kidney disease, stage 3a | 4 (1.4) | 5.1 (1.9) | 6.4 (2.2) | 0.14 | 0.18 | 0.22 | |
N18.30: Chronic kidney disease, stage 3 unspecified | 3.6 (0.3) | 3.8 (0.4) | 4.2 (0.5) | 1.83 | 1.91 | 2.13 | |
N18.32: Chronic kidney disease, stage 3b | 2.5 (1.0) | 3.2 (1.2) | 5.1 (1.9) | 0.90 | 0.12 | 0.19 | |
Diseases of the musculoskeletal system and connective tissue | |||||||
M62.59: Muscle wasting and atrophy, not elsewhere classified, multiple sites | NS | 4.1 (2.1) | NS | NS | 0.10 | NS | |
M65.071: Abscess of tendon sheath, right ankle and
foot |
NS |
NS |
280.3 (550.3) |
NS |
NS |
0.10 |
|
Diseases of the nervous system | |||||||
G62.81: Critical illness polyneuropathy | 11.8 (6.8) | 9.1 (6.8) | NS | 0.70 | 0.50 | NS | |
G93.3: Postviral fatigue syndrome | 6.8 (2.5) | 4.2 (2.1) | NS | 0.12 | 0.70 | NS | |
G72.81: Critical illness myopathy | 5 (1.5) | NS | NS | 0.30 | NS | NS | |
R51.9: Headache, unspecified |
2.6 (0.3) |
3.9 (0.3) |
3.9 (0.4) |
1.47 |
2.23 |
2.23 |
|
Diseases of the respiratory system | |||||||
J12.81: Pneumonia due to SARS-associated coronavirus | 8.5 (3.6) | NS | NS | 0.90 | NS | NS | |
J80: Acute respiratory distress syndrome | 7.4 (2.9) | 3.9 (1.7) | NS | 0.32 | 0.17 | NS | |
J95.851: Ventilator associated pneumonia | 5.2 (2.4) | 4 (2.1) | NS | 0.90 | 0.70 | NS | |
J12.89: Other viral pneumonia |
NS |
16.1 (2.6) |
11 (2.0) |
NS |
1.33 |
0.91 |
|
Diseases of skin and subcutaneous tissue | |||||||
L65.9: Nonscarring hair loss, unspecified | 2.4 (0.5) | 3.5 (0.7) | 2.3 (0.6) | 0.36 | 0.54 | 0.35 | |
L89.153: Pressure ulcer of sacral region, stage 3 | 1.7 (0.4) | NS | NS | 0.42 | NS | NS | |
L89.154: Pressure ulcer of sacral region, stage 4 |
1.6 (0.3) |
NS |
NS |
0.68 |
NS |
NS |
|
Endocrine, nutritional, and metabolic diseases | |||||||
E87.71: Transfusion associated circulatory overload |
4.9 (3.0) |
NS |
NS |
0.40 |
NS |
NS |
|
Mental, behavioral, and neurodevelopmental disorders | |||||||
F10.139: Alcohol abuse with withdrawal, unspecified |
8.8 (7.6) |
NS |
NS |
0.30 |
NS |
NS |
|
Neoplasms | |||||||
C83.90: Non-follicular (diffuse) lymphoma, unspecified,
unspecified site |
411 (807) |
272.6 (535.2) |
NS |
0.14 |
0.90 |
NS |
|
Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified | |||||||
R74.01: Elevation of liver transaminase levels | 4.8 (1.2) | 5 (1.4) | 6.5 (1.9) | 0.21 | 0.21 | 0.28 |
*Results are significant at p<0.05. Diagnoses are limited to those with RRs significantly increased at >60 d. Clinical Classification Software Refined categories were taken from Agency for Healthcare Research and Quality Clinical Classifications Software Refined (https://www.hcup-us.ahrq.gov/toolssoftware/ccsr/ccs_refined.jsp). NS, not significant; RR, relative rate. †A specific diagnosis is counted for each patient encounter so that 1 patient might contribute >1 diagnosis if they were admitted for that diagnosis more than once during time period of interest.
1These authors contributed equally to this article.